Lantus in Prediabetes
NCT00348972 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2006-07-06
Summary
To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).
Conditions
Interventions
- DRUG
-
Lantus® (insulin glargine)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Peter JOHNSTON, MD · Sanofi
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2002-02-28
Countries
- United States
Study Locations
More Related Trials
-
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
NCT00046462 ·Status: COMPLETED ·Phase: PHASE3
-
Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin
NCT00338104 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
NCT00694122 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
NCT01499095 ·Status: COMPLETED ·Phase: PHASE3
-
An Open Therapeutic Project to Confirm the Efficacy Tolerability and Safety Profile of Lantus in Everyday Medical Practice
NCT00576368 ·Status: COMPLETED ·Phase: PHASE4
-
Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus
NCT00565162 ·Status: COMPLETED ·Phase: PHASE4
-
Assessment of Duration of Metabolic Effect of a Single Bolus of sc Injected Lantus Compared to NPH Insulin in Patients With Type 2 Diabetes
NCT00553020 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Effectiveness Study of Insulin Glargine (LANTUS) Initiation and Titration in Patients With Type 2 Diabetes
NCT01127269 ·Status: COMPLETED ·Phase: PHASE4
-
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
NCT00423215 ·Status: COMPLETED
-
Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use
NCT01500850 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants
NCT03555305 ·Status: COMPLETED ·Phase: PHASE1
-
LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus
NCT00349986 ·Status: TERMINATED ·Phase: PHASE4
-
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
NCT01206712 ·Status: COMPLETED
-
Insulin Glargine Versus Twice-Daily NPH
NCT00687453 ·Status: TERMINATED ·Phase: PHASE4
-
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
NCT00511472 ·Status: COMPLETED ·Phase: PHASE1
-
Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy
NCT02855684 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy
NCT01676220 ·Status: COMPLETED ·Phase: PHASE3
-
Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes
NCT00174681 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)
NCT02059187 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus
NCT01689142 ·Status: COMPLETED ·Phase: PHASE3
-
Glycemic Optimization Treatment Study
NCT00552370 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)
NCT02059161 ·Status: COMPLETED ·Phase: PHASE3
-
LANCGMS - Lantus Continuous Glucose Monitoring Subcutaneous
NCT00322075 ·Status: COMPLETED ·Phase: PHASE4
-
Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus
NCT01226043 ·Status: COMPLETED ·Phase: PHASE4
-
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
NCT00539448 ·Status: COMPLETED ·Phase: PHASE4